AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
A phase 2 trial of Shark cartilage in Multiple myeloma, run by AEterna Zentaris, completed.
Overview
AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT00022282 by AEterna Zentaris, started 2001-04 and reaching its primary completion in 2007-03. Interventions recorded: shark cartilage extract AE-941. Conditions recorded: Multiple Myeloma and Plasma Cell Neoplasm.
Linked to the technology Shark cartilage because the registry names it ("shark cartilage") among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialShark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer
Shares Shark cartilage (AE-941, Neovastat) and the tag pipeline.
- TrialCombination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
Shares Shark cartilage (AE-941, Neovastat) and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Shares Multiple myeloma and the tag pipeline.
- TrialPamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Shares Multiple myeloma and the tag pipeline.